Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Muscular Atrophy 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 ER+ and AR+ Breast Cancer 2 Lymphoma, Non-Hodgkin 1 Colorectal Neoplasms 1 Cachexia 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

bicalutamide 5 enzalutamide 4 exemestane 2 darolutamide 2 abiraterone 2 pembrolizumab 1 ostarine 1 nilutamide 1 cabazitaxel 1 apalutamide 1 abemaciclib 1 Vorinostat 1 Triptorelin Pamoate 1 Tamoxifen 1 Prophylactic Mastectomy 1 Prednisolone 1 Panobinostat 1 Mifepristone 1 Letrozole 1 Histamine H2 Antagonists 1 Histamine Antagonists 1 Goserelin 1 Doxorubicin 1 Docetaxel 1 Dasatinib 1 Cisplatin 1 CP protocol 1 Aromatase Inhibitors 1 Antiemetics 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Bulbo-Spinal Atrophy, X-Linked × ostarine × Clear all

NCT04869943 2024-01-26

ARTEST

Veru Inc.

Phase 3 Terminated

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡